AIM 2- Prevention of Neonatal Abstinence Syndrome

Trial Profile

AIM 2- Prevention of Neonatal Abstinence Syndrome

Phase of Trial: Phase II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Ondansetron (Primary) ; Ondansetron (Primary)
  • Indications Substance withdrawal syndrome
  • Focus Therapeutic Use
  • Acronyms AIM2NAS
  • Most Recent Events

    • 15 Apr 2016 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.
    • 15 Apr 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Apr 2017.
    • 26 Jun 2014 Status changed from suspended to recruiting as reported by record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top